Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion
NASDAQ:ANIP

ANI Pharmaceuticals 9/8/2025 Earnings Report

ANI Pharmaceuticals logo
$80.12 +0.78 (+0.98%)
As of 11:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.

ANI Pharmaceuticals EPS Results

Actual EPS
$1.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

ANI Pharmaceuticals Revenue Results

Actual Revenue
$211.37 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ANI Pharmaceuticals Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

ANI Pharmaceuticals Earnings Headlines

I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
See More ANI Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ANI Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ANI Pharmaceuticals and other key companies, straight to your email.

About ANI Pharmaceuticals

ANI Pharmaceuticals (NASDAQ:ANIP) is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care. Alongside its proprietary generics business, ANI provides contract development and manufacturing organization (CDMO) services, leveraging its integrated in-house capabilities in sterile and nonsterile production, analytical testing and regulatory support to meet the needs of pharmaceutical partners.

Primarily serving markets in North America, ANI maintains multiple U.S. manufacturing facilities certified for complex sterile and nonsterile operations. The company collaborates with major distributors, retail pharmacies, hospitals and healthcare systems, and continues to invest in process optimization and quality systems to expand its product pipeline and support evolving patient needs.

View ANI Pharmaceuticals Profile